Latin America Viral Vector Manufacturing Market Report and Forecast 2024-2032

Latin America Viral Vector Manufacturing Market Report and Forecast 2024-2032

Latin America Viral Vector Manufacturing Market Report and Forecast 2024-2032

Latin America Viral Vector Manufacturing Market Size

The global viral vector manufacturing market was valued at USD 2.6 billion in 2023, with Latin America holding a significant market share. It is expected to grow at a CAGR of 19.74% during the forecast period of 2024-2032 and attain a market value of USD 13.5 billion by 2032, driven by the increasing awareness about gene therapy across the region.

Latin America Viral Vector Manufacturing Market Outlook

• In March 2024, the National Health Surveillance Agency (Anvisa) of Brazil approved the world's first gene therapy Biomarin’s Roctavian for severe adults with hemophilia A. This approval may contribute to increased adoption of viral vector manufacturing in the region.
• The market is witnessing surge in mergers and acquisitions, projected to boost the market value in the forecast period. In March 2024, a foundation from the Brazilian government's Ministry of Health, and Caring Cross, anon-profit organisation collaborated to develop local manufacturing of (CAR)-T cell and stem cell gene therapies for oncology, infectious, and genetic diseases in Brazil.
• Brazil has seen a significant increase in the number of dengue cases over the past four years. As of 2024, there have been 232,900 reported cases and 161 deaths. This has created a demand for the development of new vaccines, leading to growth in the market.

Latin America Viral Vector Manufacturing Market Analysis

Viral vectors are efficient gene transfer vehicles that are commonly used by molecular biologists to manipulate a specific cell type or tissue for certain therapeutic purposes. Regulatory approvals play a pivotal role in the distribution of therapeutics, and diagnostics in the market among other healthcare products and services while adding credibility at the same time. The market is propelled by the approvals of newly developed gene therapies by the regulatory authorities in the region. For instance, in March 2024, the National Health Surveillance Agency (Anvisa) of Brazil approved world's first gene therapy Biomarin’s Roctavian (valoctocogene roxaparvovec) for severe hemophilia A. The approval is expected to foster increased investments in local manufacturing capabilities and technologies, thereby, enhancing the Latin America viral vector manufacturing market share.

The market is witnessing strategic collaborations, which is supporting viral vector manufacturing and its application in various healthcare domains. For instance, in March 2024, a collaboration was announced by the Brazilian government's Ministry of Health foundation, Fundação Oswaldo Cruz (Fiocruz) and Caring Cross, to support the advancement of local manufacturing of chimeric antigen receptor (CAR)-T cell and stem cell gene therapies for oncology, infectious, and genetic diseases in Brazil. This also includes CAR-T cell therapies for leukemia, lymphoma, and HIV infection. The Caring Cross is a non-profit organisation, aimed at improving the development of innovative medicines and providing access to advanced medicinal. Such partnerships are expected to boost the Latin America viral vector manufacturing market growth in the forecast period.

The market demand is also projected to be positively impacted by the rising infectious diseases in the region. For instance, Bueno Aires has registered around 232,900 dengue cases and 161 deaths within the first 8 weeks of 2024. This outbreak has been considered the worst in 4 years. Increasing cases of dengue in Argentina create a pressing need to develop a vaccine in the region to overcome this outbreak. This will contribute to the increased demand for vaccines and therapeutics in the region, propelling the Latin America viral vector manufacturing market size. The rising demand can attract investors and expansions in the facilities needed for the production of viral vectors, which are crucial for manufacturing certain types of vaccines. As a result, the market is poised to be driven by the pressing need to develop more advanced technologies to assist vaccine development.

Latin America Viral Vector Manufacturing Market Segmentation  

The report offers a detailed analysis of the market based on the following segments:

Market Breakup by Type

Adenoviral Vectors

Adeno-Associated Viral (AAV) Vectors

Lentiviral Vectors

Retroviral Vectors

Others

Market Breakup by Application

Gene Therapy

Cell Therapy

Others

Market Breakup by Therapeutic Area

Oncological Disorders

Neurological Disorders

Metabolic Disorders

Immunological Disorders

Others

Market Breakup by End User

Research Organizations

Biotech and Pharmaceutical Companies

Others

Market Breakup by Country

Brazil

Argentina

Mexico

Others

Leading Players in the Latin America Viral Vector Manufacturing Market

The key features of the market report include patent analysis, grants analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows: 

• Lonza Group AG
• Merck KGaA
• Thermo Fisher Scientific Inc.
• Catalent, Inc.
• Danaher Corporation
• Sartorius AG
• Fujifilm Group
• Novartis AG
• Charles River Laboratories
• Laboratorios Liomont

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report. 

FAQs

• What was the Latin America viral vector manufacturing market forecast outlook in 2024-2032?

The Latin America viral vector manufacturing market is expected to be driven by the rising demand for global market, which is anticipated to grow at a CAGR of 19.7% during the forecast period of 2024-2032 and is likely to reach a market value of USD 8.1 billion by 2032.

• What are the major factors aiding the Latin America viral vector manufacturing market demand?  

The market is driven by the increasing awareness of biotechnology and gene therapy for the treatment of several diseases.

• What are the major Latin America viral vector manufacturing market trends? 

The market growth is influenced by increasing collaboration and partnerships in the region. For instance, in March 2024, Caring Cross and Fiocruz collaborated to improve access to cell and gene therapies in the region.

• What are the various types of viral vector manufacturing?

Various types include adenoviral vectors, adeno-associated viral (AAV) vectors, lentiviral vectors, retroviral vectors, and others.

• What are the various applications of viral vector manufacturing?

Viral vector manufacturing has applications in gene therapy, cell therapy, and vaccines.

• What are the therapeutic areas of viral vector manufacturing?

Therapeutic areas include oncological disorders, neurological disorders, metabolic disorders, immunological disorders, and others.

• Who are the end users in the market?

End users in the market include research organizations, biotech and pharmaceutical companies, and others.

• What is the market segmentation by country? 

The market segmentation by countries includes Brazil, Argentina, Mexico, and others.

• Who are the key players in the Latin America viral vector manufacturing market?

The key players in the market are Lonza Group AG, Merck KGaA, Thermo Fisher Scientific Inc., Catalent, Inc., Danaher Corporation, Sartorius AG, Fujifilm Group, Novartis AG, Charles River Laboratories, and Laboratorios Liomont.

Meta description

The Latin America viral vector manufacturing market size is poised for growth, driven by the expansion of the global market, which was valued at USD 2.6 billion in 2023 and is projected to grow at a CAGR of 19.74% during the forecast period of 2024-2032.

*Please Note:* The report will take 7 business days to complete, after order confirmation.